Human Embryonic Stem Cells Market Size (2024 - 2029)

The human embryonic stem cell market is anticipated to experience substantial growth, driven by factors such as the increasing prevalence of cardiac and malignant diseases, a rising demand for regenerative medicines, and enhanced support from government and private institutions. The market's expansion is further supported by the focus on stem cell therapies for COVID-19 management, which spurred numerous clinical trials and research initiatives. Despite these growth drivers, challenges such as high procedural costs and stringent regulatory requirements may hinder market expansion.

Home Market Analysis Healthcare Research Biotechnology Research Biotechnology R&D Research Life Science Research Technologies Research Stem Cell Research Stem Cell Banking Industry Market Size

Market Size of Human Embryonic Stem Cells Industry

Human Embryonic Stem Cells Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 9.29 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Human Embryonic Stem Cells Market Major Players

*Disclaimer: Major Players sorted in no particular order

Human Embryonic Stem Cells Market Analysis

The human embryonic stem cell market is expected to witness a CAGR of 9.29% over the forecast period.

  • The COVID-19 pandemic had a significant impact on the growth of the market, which was majorly due to the rising number of clinical trials and the growing research on stem cell therapies for effective management of COVID-19 infection. In the context of COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms were focusing on effective and rapid technologies for the fast diagnosis and treatment of COVID-19. 
  • For instance, according to a research article from PubMed published in April 2020, it was found that mesenchymal stem cells are safe and effective for the treatment of COVID-19. Mesenchymal Stem Cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach. The positive results from such studies led to the development of new therapies for COVID-19 and thus propelled the growth of the market. Currently, the market has reached its pre-pandemic nature and is expected to witness strong growth in the coming years.
  • The growth of the market is attributed to the high prevalence of cardiac and malignant diseases, rising demand for regenerative medicines, and increasing support from government and private institutions.
  • Government funding for the development of regenerative medicine has been increasing in most developed countries, owing to its applications in organ transplantation, tissue engineering, and various other applications. For instance, in June 2021, The Australian Government boosted stem cell research through USD 25 million in grants to help find and develop innovative, safe, and effective treatments for serious diseases and injuries.
  • The area of human embryonic stem cell-based therapies garners significant investments, and various clinical trials that require considerable support for expenditure are currently underway. Companies are fundraising to develop stem cell-based therapies to tackle many diseases. For instance, in January 2022, Cellino Biotech, a cell therapy manufacturing company, raised USD 80 million in a Series A financing round. Cellino plans to expand access to stem cell-based therapies by building the first autonomous human cell foundry in 2025.
  • Additionally, other factors, such as the high prevalence of cardiac and malignant diseases and the rising demand for regenerative medicines, are expected to drive the market. According to the data published by the European Heart Network in 2021, in the European Union, more than 60 million people live with Cardiovascular disease, and close to 13 million new cases of cardiovascular diseases are diagnosed every year. Such incidences of cardiac diseases are expected to drive the demand for effective therapeutics, such as embryonic stem cell therapies, thereby contributing to the growth of the market.
  • Thus, owing to the abovementioned factors, the market is expected to project significant growth over the forecast period. However, the high cost of the procedure and stringent regulatory scenario are expected to restrain the growth of the market over the forecast period.

Human Embryonic Stem Cells Industry Segmentation

Human embryonic stem cells are pluripotent stem cells that are extracted from the inner cell mass of a blastocyst, which is an early-stage pre-implantation embryo. These stem cells are used for the treatment of various diseases. 

The human embryonic stem cells market is segmented by application (regenerative medicine, stem cell biology research, tissue engineering, and toxicology testing) and geography (North America, Europe, Asia-Pacific, the Middle East, Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. 

The report offers the value (in USD) for the above segments.

By Application
Regenerative Medicine
Stem Cell Biology Research
Tissue Engineering
Toxicology Testing
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Human Embryonic Stem Cells Market Size Summary

The human embryonic stem cell market is poised for significant growth, driven by the increasing prevalence of chronic diseases and the rising demand for regenerative medicines. The market's expansion is supported by substantial investments and funding from both government and private sectors, aimed at advancing research and development in stem cell therapies. The COVID-19 pandemic acted as a catalyst for market growth, as it spurred numerous clinical trials and research initiatives focused on stem cell-based treatments for the virus. This surge in research has led to the development of new therapies, restoring the market to its pre-pandemic trajectory and setting the stage for robust growth in the coming years. Despite the promising outlook, challenges such as high procedural costs and stringent regulatory environments may pose constraints to market expansion.

Regionally, North America is expected to maintain a significant share of the market, bolstered by extensive research activities and a high burden of chronic diseases. The United States, in particular, is witnessing increased research funding and regulatory approvals for stem cell-derived therapies, which are anticipated to drive market growth. The competitive landscape of the market is moderately fragmented, with several global and regional players actively participating. Companies like Astellas Pharma Inc., Merck KGaA, and Thermo Fisher Scientific are prominent in the market, contributing to its dynamic nature. Collaborative efforts and funding initiatives, such as those by Aspen Neuroscience and TreeFrog Therapeutics, further underscore the market's potential for innovation and growth in the field of stem cell biology and regenerative medicine.

Explore More

Human Embryonic Stem Cells Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 High Prevalence of Cardiac and Malignant Diseases

      2. 1.2.2 Rising Demand for Regenerative Medicines

      3. 1.2.3 Increasing Support from Governments and Private Institutions

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of the Procedure

      2. 1.3.2 Stringent Regulatory Guidelines

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Application

      1. 2.1.1 Regenerative Medicine

      2. 2.1.2 Stem Cell Biology Research

      3. 2.1.3 Tissue Engineering

      4. 2.1.4 Toxicology Testing

    2. 2.2 Geography

      1. 2.2.1 North America

        1. 2.2.1.1 United States

        2. 2.2.1.2 Canada

        3. 2.2.1.3 Mexico

      2. 2.2.2 Europe

        1. 2.2.2.1 Germany

        2. 2.2.2.2 United Kingdom

        3. 2.2.2.3 France

        4. 2.2.2.4 Italy

        5. 2.2.2.5 Spain

        6. 2.2.2.6 Rest of Europe

      3. 2.2.3 Asia-Pacific

        1. 2.2.3.1 China

        2. 2.2.3.2 Japan

        3. 2.2.3.3 India

        4. 2.2.3.4 Australia

        5. 2.2.3.5 South Korea

        6. 2.2.3.6 Rest of Asia-Pacific

      4. 2.2.4 Middle East and Africa

        1. 2.2.4.1 GCC

        2. 2.2.4.2 South Africa

        3. 2.2.4.3 Rest of Middle East and Africa

      5. 2.2.5 South America

        1. 2.2.5.1 Brazil

        2. 2.2.5.2 Argentina

        3. 2.2.5.3 Rest of South America

Human Embryonic Stem Cells Market Size FAQs

The Global Human Embryonic Stem Cells Market is projected to register a CAGR of 9.29% during the forecast period (2024-2029)

Merck KGaA, STEMCELL Technologies Inc., Thermo Fisher Scientific, Lineage cell therapeutics and ViaCyte Inc are the major companies operating in the Global Human Embryonic Stem Cells Market.

Human Embryonic Stem Cells Market Report Snapshots

Human Embryonic Stem Cells Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)